Search results for "coagulation factor"

showing 5 items of 45 documents

Acquired haemophilia in cancer: A systematic and critical literature review

2017

Aim There is a paucity of data on the clinical presentation and management of cancer patients with acquired haemophilia (AH), we here report a systematic literature review on acquired haemophilia in the context of cancer. Methods Treatment outcomes of AH were defined as complete response (CR), partial response (PR) or no response (NR), based on inhibitor eradication, coagulation factor VIII levels and bleeding control. Reported deaths were either related to cancer or bleeding. Results Overall, 105 cases were collected and analyzed according to classification of cancer and efficacy of treatments for inhibitor and malignancy. The mean age was 68 years for both males (range 37-86 years) and fe…

medicine.medical_specialtyContext (language use)Antineoplastic AgentsFactor VIIa030204 cardiovascular system & hematologyMalignancyHemophilia AGastroenterology03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineNeoplasmsAcquired haemophiliamedicineHumanscancerhaematological malignancyGenetics (clinical)Blood Coagulation Factor Inhibitorstreatmentbusiness.industryIncidence (epidemiology)AutoantibodyCancerHematologyGeneral Medicinemedicine.diseasebleedingBlood Coagulation FactorsRecombinant ProteinsSurgeryinhibitordiagnosiSystematic reviewTreatment Outcome030220 oncology & carcinogenesisHematologic Neoplasmsacquired haemophilabusinessHaematological malignancy
researchProduct

Missense Mutations in the Proline-Rich Region of Coagulation Factor XII in Hereditary and Idiopathic Angioedema.

2006

Abstract Hereditary angioedema (HAE) is characterized by recurrent skin swelling, abdominal pain attacks, and potentially life-threatening upper airway obstruction. The two classic HAE types (I and II) are caused by mutations in the complement C1 inhibitor gene, resulting in a functional deficiency of C1 inhibitor. Recently, a novel type of hereditary angioedema has been described, these patients showing normal C1 inhibitor concentration and activity in plasma (HAE with normal C1 inhibitor, HAE type III). With few exceptions, all reported patients have been women, and exposition to estrogens appears to be an important precipitating factor. Screening of twenty unrelated female patients with …

medicine.medical_specialtyFactor XIIMutationAngioedemabiologybusiness.industryImmunologyCell BiologyHematologyCoagulation Factor XIImedicine.disease_causemedicine.diseaseBiochemistryC1-inhibitorExonEndocrinologyInternal medicineHereditary angioedemamedicinebiology.proteinMissense mutationmedicine.symptombusinessBlood
researchProduct

Hereditary angioneurotic oedema and blood-coagulation: interaction between C1-esterase-inhibitor and the activation factors of the proteolytic enzyme…

1983

C-1-inactivator (C-1-INA) does not only exert its important inhibitory functions in the complement system but also in the first step in the activation of the coagulation, fibrinolytic and kallikrein system. We therefore determined in nine patients with hereditary angioneurotic oedema (HANE) with obvious quantitative or functional defects of C-1-INA, and one further patient with Quincke-type oedema of different origin, the coagulation factors of the initial phase such as Hageman factor, plasma thromboplastin antecedent (PTA) and high molecular weight kininogen (HMWK). These factors were further correlated with the concentration as well as functional activity of C-1-INA. Nine of ten patients …

medicine.medical_specialtyHigh-molecular-weight kininogenInternal medicineDrug DiscoverymedicineHumansAngioedemaFactor XIBlood CoagulationGenetics (clinical)Factor XIFactor XIIComplement C1sChemistryKininogensProteolytic enzymesGeneral MedicineKallikreinMolecular medicineBlood Coagulation FactorsComplement systemEnzyme ActivationEndocrinologyCoagulationFactor XIIMolecular MedicinePeptide HydrolasesKlinische Wochenschrift
researchProduct

Interaction between C1-INA, coagulation, fibrinolysis and kinin system in hereditary angioneurotic edema (HANE) and urticaria.

1984

The C1-inactivator plays an important role not only in the initial phases of the complement system, but also in those of the coagulation, fibrinolysis and kinin systems. The present study was concerned with the reciprocal influence of decreased C1-inactivator levels in patients with hereditary angioneurotic edema (HANE, HAE). In 13 HANE-I patients there were significantly increased levels of the coagulation factors XII, XI, V, of plasminogen and of alpha 2-antiplasmin, while the factors IX and VII were decreased. Conversely, it emerged that in patients with markedly raised prephase factor levels, angioneurotic edema occurred in the presence of normal or only slightly decreased C1-inactivato…

medicine.medical_specialtyUrticariaHereditary angioneurotic edemamedicine.medical_treatmentDermatologyKininsComplement C1 Inactivator Proteinschemistry.chemical_compoundInternal medicineEdemaFibrinolysismedicineHumansAngioedemaFactor XIIAngioedemaFactor VIIbusiness.industryFibrinolysisGeneral MedicineKininBlood Coagulation FactorsEndocrinologyCoagulationchemistryImmunologymedicine.symptombusinessArchives of dermatological research
researchProduct

Dental treatment of patients with coagulation factor alterations: An update

2007

Hemostasia is a defense mechanism that protects vascular integrity, avoids blood loss, and maintains blood fluidity throughout the circulatory system. The biochemical processes leading to blood clot formation are complex, and alterations can appear at any point within the chain of events. While a range of alterations can affect the coagulation factors, some are more common than others in the general population, including congenital (hemophilia A and B, Von Willebrand’s disease) and acquired disorders (anticoagulant drugs). Such diseases require special consideration in the context of dental treatment, and therefore must be known to dental professionals. Interconsultation with the hematologi…

prevencióninterconsultaanticoagulant drugscoagulation factors:CIENCIAS MÉDICAS [UNESCO]hemofiliapreventionVon Willebrand’s diseasehemophiliaUNESCO::CIENCIAS MÉDICASfactores de coagulaciónHemostasiaenfermedad de von WillebrandVon Willebrand’s diseasefármacos anticoagulantesaccidentes hemorrágicosinterconsultationbleeding accidents
researchProduct